Discover the challenges facing Leqembi, the first Alzheimer's drug shown to slow progression. Skepticism among doctors and concerns about efficacy and costs hinder widespread adoption despite FDA approval.
Nine months after the U.S. launch of Eisai Limited ESALY and Biogen Inc’s BIIB Leqembi, the first drug shown to slow Alzheimer’s progression, adoption faces…
Canada invests in research to improve sleep for Canadians miragenews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from miragenews.com Daily Mail and Mail on Sunday newspapers.
Share this article
Now available in Canada for the treatment of insomnia in adults
MISSISSAUGA, ON, Feb. 4, 2021 /CNW/ - Eisai Limited, the Canadian subsidiary of Eisai Inc., today announced the Canadian authorization and availability of a new non-sedative prescription medication, DAYVIGO™ (lemborexant). Available in both 5 mg and 10 mg dosages, DAYVIGO is indicated for the treatment of insomnia, characterized by difficulties with sleep onset and / or sleep maintenance.
1
DAYVIGO is now available in Canada for the treatment of insomnia in adults. (CNW Group/Eisai Limited)
Already approved in the United States and Japan for the treatment of insomnia, the Canadian authorization of DAYVIGO is based on two pivotal phase three studies, which established the efficacy and safety profile of the medication.